Abstract
This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Keywords: Complications, meningococcal disease, serogroup B.
Infectious Disorders - Drug Targets
Title:Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Volume: 14 Issue: 3
Author(s): Fereshteh Dastouri, Ahmad Mirmohammad Hosseini, Elizabeth Haworth, Gulam Khandaker, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Complications, meningococcal disease, serogroup B.
Abstract: This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Export Options
About this article
Cite this article as:
Dastouri Fereshteh, Mirmohammad Hosseini Ahmad, Haworth Elizabeth, Khandaker Gulam, Rashid Harunor and Booy Robert, Complications of Serogroup B Meningococcal Disease in Survivors: A Review, Infectious Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871526515999150320155614
DOI https://dx.doi.org/10.2174/1871526515999150320155614 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synergistic Effect of Combined HIV/HCV Immunogens: A Combined HIV-1/HCV Candidate Vaccine Induces a Higher Level of CD8+ T Cell-Immune Responses in HLA-A2.1 Mice
Current HIV Research Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Acanthamoeba-Bacteria: A Model to Study Host Interaction with Human Pathogens
Current Drug Targets Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology Pulmonary Vaccine Delivery Systems: A Novel Approach for Immunization
Current Drug Therapy CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of Melatonin in Neurological Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) QSAR Studies on HSV-1 Inhibitors by CoMFA, CoMSIA and HQSAR Approaches
Letters in Drug Design & Discovery Nitric Oxide in Migraine
CNS & Neurological Disorders - Drug Targets Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System
Current Neuropharmacology Computational Biology Tools for Identifying Specific Ligand Binding Residues for Novel Agrochemical and Drug Design
Current Protein & Peptide Science